[Lab] CPC cagri — Janoshik came back 98.4% against a claimed 97.5%
Title says it — CPC cagri — Janoshik came back 98.4% against a claimed 97.5% — so here is the boring supporting detail that makes it worth anything. The relevant figures are 98.4% and 97.5%, and they come from the same log I have kept the whole time. Independent purity data on this compound is sparse compared with…
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
amylin analogue, different receptor family, different story
Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.
Which receptor family are you attributing that effect to?
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
nothing containing this is approved as a standalone product
Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.